SCHEMBL6101263

SCHEMBL6101263

C=CCNc1ccccc1/C=N\O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.49
TSHR P16473 2/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
NPSR1 Q6W5P4 1/20 0.41
RRM2 P31350 1/20 0.41
ALDH1A1 P00352 4/20 0.38
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HTT P42858 2/20 0.36
FGF23 Q9GZV9 1/20 0.36
ELANE P08246 2/20 0.35
PRTN3 P24158 1/20 0.35
LMNA P02545 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
MAPT P10636 2/20 0.35
NPC1 O15118 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6101267 1.00 HPGD (0.49) HPGDTSHRMAPK1HSD17B10NPSR1
SCHEMBL472991 0.80 ALDH1A1 (0.40) HPGDRRM2ALDH1A1RAB9ASMN1; SMN2
SCHEMBL4784858 0.77 ALDH1A1 (0.44) HPGDRRM2ALDH1A1RAB9ASMN1; SMN2
SCHEMBL4410008 0.77 KMT2A (0.44) HPGDTSHRALDH1A1RAB9ASMN1; SMN2
SCHEMBL6096883 0.72 L3MBTL1 (0.40) HPGDTSHRMAPK1HSD17B10NPSR1
SCHEMBL6096888 0.72 L3MBTL1 (0.40) HPGDTSHRMAPK1HSD17B10NPSR1
SCHEMBL796531 0.72 KMT2A (0.48) HPGDMAPK1RRM2ALDH1A1RAB9A
SCHEMBL5824157 0.71 KMT2A (0.49) HPGDMAPK1HSD17B10RRM2ALDH1A1
SCHEMBL26064904 0.71 CA12 (0.41) HPGDRRM2ALDH1A1RAB9ASMN1; SMN2
SCHEMBL12253483 0.70 ALDH1A1 (0.40) HPGDHSD17B10RRM2ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6998489-B2 Methods of making indazoles ALCON, INC. (CH) 2006-02-14 US disclosed
EP-1392659-A4 METHODS OF MAKING INDAZOLES ALCON INC (CH) 2004-10-20 EP disclosed
US-20040142998-A1 Methods of making indazoles ALCON, INC. (CH) 2004-07-22 US disclosed
EP-1392659-A1 METHODS OF MAKING INDAZOLES Alcon, Inc. (CH) 2004-03-03 EP disclosed
WO-2002098861-A1 METHODS OF MAKING 1-(2-AMINOPROPYL)-6-HYDROXYINDAZOLE ALCON, INC. (CH) 2002-12-12 WO disclosed
WO-2002098862-A1 METHODS OF MAKING INDAZOLES ALCON, INC. (CH) 2002-12-12 WO disclosed
EP-0076404-B1 METHOD FOR RECOVERY OF GALLIUM SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1986-01-29 EP disclosed
US-4468374-A AMIDOOXIME CHELATE RESIN SIMITOMO CHEMICAL COMPANY, LIMITED (JP) 1984-08-28 US disclosed
EP-0076404-A1 Method for recovery of gallium SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1983-04-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142998-A1 Methods of making indazoles NAT1, CYP3A5, ALDH3A1 HPGD 105/4885TSHR 4510/4885MAPK1 4463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.